October 2024

Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study

RMD Open 2024;12:e004476 doi: 10.1136/rmdopen-2024-004476

Buch et al. demonstrated that filgotinib sustained its efficacy in rheumatoid arthritis patients through Wk156 in the FINCH 4 long-term extension study, showing stable safety profiles. The study reported high ACR response rates and remission based on Boolean criteria, underlining filgotinib's potential for extended clinical benefits.

Keywords:

September 2024

A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis

Skin Res Technol. 2024 Sep;30:e70041 doi: 10.1111/srt.70041

Ghani et al. compared the efficacy and safety profiles of tapinarof and roflumilast for treating mild-to-moderate plaque psoriasis. Both therapies showed robust efficacy and were well-tolerated, with low rates of adverse events. Tapinarof exhibited marginally higher efficacy in PASI scores compared to roflumilast.

Keywords:

A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis

Br J Dermatol. 2024 Aug 14;191:336-343 doi:10.1093/bjd/ljae062

Cai et al. demonstrated that xeligekimab significantly improved the Psoriasis Area and Severity Index (PASI) scores in patients with moderate-to-severe plaque psoriasis, with 90.7% achieving PASI 75 at week 12. Xeligekimab was well-tolerated with no unexpected safety concerns.

Keywords:

Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From the Randomized, Placebo-Controlled, Phase III INVIGORATE-1 Study

Arthritis Rheumatol. 2024 Sep 19 doi 10.1002/art.42993 Epub ahead of print

Deodhar et al. evaluated the efficacy and safety of intravenous secukinumab in patients with active axial spondyloarthritis. The study found a significant improvement in the ASAS40 response at Week 16 (40.9% vs 22.9% in placebo, P<0.0001), with responses maintained through Week 52. No new safety signals were observed.

Keywords:

Efficacy and safety of intravenous secukinumab for the treatment of active psoriatic arthritis: Results from the randomized, placebo-controlled Phase III INVIGORATE-2 study

Arthritis Rheumatol 2024 doi: 10.1002/art.42997

IV secukinumab provided rapid and sustained improvements in disease signs and symptoms at Week 16 and through 52 weeks. Kivitz et al. evaluated the long-term efficacy, safety, and tolerability of IV secukinumab in patients with active PsA.

Keywords:

Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib

Modern Rheumatology 2024;34:1115–24 doi: 10.1093/mr/roae030

Tanaka et al. observed that in Japanese patients with rheumatoid arthritis treated with tofacitinib, those with absolute lymphocyte counts (ALCs) <0.5x10³ cells/mm³ had a higher risk of serious infections and herpes zoster events compared to patients with higher ALC levels. This threshold may help identify increased infection risk in this population

Keywords:

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate

Rheumatology, 2024. Epub ahead of print doi: 10.1093/rheumatology/keae486

Buch et al. evaluated the efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and inadequate response to methotrexate in the FINCH 1 study. At     Wk 12, ACR20 response rates were significantly higher with filgotinib 200 mg (77.9%) and 100 mg (67.8%) compared to placebo (43.8%). Safety profiles for both filgotinib doses were similar to adalimumab.

Keywords:

Risankizumab for Ulcerative Colitis Two Randomized Clinical Trials

JAMA. 2024;332:881-897 doi: 10.1001/jama.2024.12414

Louis et al. demonstrated risankizumab to significantly improve clinical remission rates compared to placebo in both an induction trial and in a maintenance trial for patients with moderately to severely active ulcerative colitis.

Keywords:

Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis

N Engl J Med. 2024;391:1119-1129 doi: 10.1056/NEJMoa23140

Sands et al. demonstrated that 12-week treatment of tulisokibart, a monoclonal antibody targeting TL1A, significantly improved clinical remission rates compared to placebo in patients with moderate-to-severe ulcerative colitis.

Keywords:

Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis

Clin Exp Dermatol. 2024 Sep 18;49:1232-1234 doi: 10.1093/ced/llae16

Napolitano et al. conducted a retrospective analysis on patients with moderate-to-severe psoriasiform atopic dermatitis (AD) treated with JAK inhibitors, showing significant improvements in disease severity scores (EASI, P-NRS, DLQI) by Week 4, with 95% of patients achieving EASI-75 and 86% achieving EASI-90 by Week 24.

Keywords: